Drugs / pentazocine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | TALWIN 50 | — | 1969-02-03 | fda.gov ↗ |
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 met primary | ||||||
| Phase 1 | NCT02070718 | Jan → Jul 2013 | — | University of Washington | Completed | Met primary |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00125931 | Sep 2005 → Aug 2008 | bipolar disorder | Mclean Hospital | Completed | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT02094339 | Mar 2014 → Jun 2016 | — | Guangzhou General Hospital of Guangzhou Military Command | Unknown | No outcome recorded |
| Phase 4 | NCT02114463 | Mar 2014 → Aug 2016 | — | Guangzhou General Hospital of Guangzhou Military Command | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05565274 | Oct 2022 → Feb 2023 | — | Federal Medical Centre, Yenagoa | Unknown | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT00431184 Comparator | Jan 2007 → Mar 2011 | manic bipolar affective disorder, schizoaffective disorder | Mclean Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02208596 Background | Sep 2014 → Feb 2015 | — | Third Affiliated Hospital of Zhengzhou University | Unknown | No outcome recorded |
| Phase 4 | NCT01872494 Comparator | May 2013 → Feb 2014 | — | Guangzhou General Hospital of Guangzhou Military Command | Completed | No outcome recorded |
| — | NCT04539249 Comparator | Nov 2020 → Mar 2021 | — | Olakunle Ifeoluwa Makinde | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pentazocine | “To establish proof of concept regarding efficacy of an oral kappa agonist (KA), Pentazocine/Naloxone 50/0.5 mg, for the treatment of menopausal hot flashes.” NCT02070718 ↗8“flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg” NCT02114463 ↗ “flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg” NCT02094339 ↗ “The effects of pentazocine, a kappa agonist, in patients with mania.” PMID 17897484 ↗ Sep 2007 |
| Action | Activate | “pentazocine, a kappa agonist” PMID 17897484 ↗ Sep 2007 |
| Route | Oral | “To establish proof of concept regarding efficacy of an oral kappa agonist (KA), Pentazocine/Naloxone 50/0.5 mg, for the treatment of menopausal hot flashes.” NCT02070718 ↗ |